1. Slide Source www.lipidsonline.org Kaplan-Meier Curve of Time to Primary End Point Proportion of Events (%) Pioglitazone Placebo PROactive investigators. Lancet 2005;366:1279-1289. 2488 2530 2302 2317 2218 2215 348 345 Pioglitazone (514 events) Placebo (572 events) 2146 2122 2373 2413 06122430 18 36 No. at Risk Time from Randomization (months) HR = 0.90 (95% CI 0.80-1.02) p = 0.095

2. Slide Source www.lipidsonline.org Kaplan-Meier Curve of Time to Secondary End Point Proportion of Events (%) Pioglitazone Placebo PROactive investigators. Lancet 2005;366:1279-1289. 2536 2566 2435 2442 2381 2371 396 390 Pioglitazone (301 events) Placebo (358 events) 2336 2315 2487 2504 06122430 18 36 No. at Risk Time from Randomization (months) HR = 0.84 (95% CI 0.72-0.98) p = 0.027

3. Slide Source www.lipidsonline.org 724824Baseline Change in Posterior-Wall Mean CIMT LS Mean Change from Baseline, mm No. of Observations Glimepiride Pioglitazone Week Glimepiride Pioglitazone 186 175 170 166 186 175 186 175 Mazzone T et al. JAMA 2006;296:2572-2581.

4. Slide Source www.lipidsonline.org 724824Baseline Change in Posterior-Wall Maximum CIMT LS Mean Change from Baseline, mm No. of Observations Glimepiride Pioglitazone Week Glimepiride Pioglitazone 186 175 170 166 186 175 186 175 Mazzone T et al. JAMA 2006;296:2572-2581.